Trial Search Results

Mild Depression 2 Week Observational Study

The purpose of this study is to assess whether the dysphoric-like depressive characteristics observed in people with epilepsy are unique to this patient population in comparison to three control groups: Mild Depression (enrolled at Stanford University), Migraine Headaches (enrolled at Long Island Jewish Medical Center), and Multiple Sclerosis (enrolled at Rush University Medical Center).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: GlaxoSmithKline

Stanford Investigator(s):


Inclusion Criteria::

" Male or female 18 years of age or older. " Presence of a Depressive disorder that
presents as a dysthymic or minor depressive disorder and whose score on the Beck Depression
Inventory (BDI) range between 11 and 20. Patients with major depression will be excluded.

" Is currently on stable doses of medications i.e., no change in treatment in the previous
30 days.

" Achieves a satisfactory score on the WRAT3 (standard score is > 69). " Is capable of
completing the self-reporting questionnaires. " Is willing and able to provide written
informed consent and comply with the study protocol Exclusion Criteria:" Presence of a
clinically significant comorbidity of an unstable or progressive nature (e.g., psychosis,
delirium) that could, in the opinion of the investigator, prevent completion of the
questionnaires or warrant immediate medical intervention.

" Participation in an investigational trial within the past 30 days. " Inability to
communicate well with site study personnel, e.g. inability to read or understand English,
poor mental development or impaired brain function.

" Patients with a clinical picture that meets criterion of major depression.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jessica Hawkins